Life Science Nation Newsletter  |  April 14, 2016  |  Issue 158

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Apr. 7 - Apr. 13)
Seeks Disruptive Medtech in Robotics, Cardiovascular, Cancer, Diabetes and Orthopedics
Seeks Advanced Medtech Platform Opportunities in USA
Seeks Data-Driven Medical Devices, Diagnostics, and Drug Adherence Tech
Seeks Medtech & Healthcare IT Deals Across the USA
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI San Francisco 2016 Investors Panel

Video Recap of RESI@TMCx 2015

By Dianne Carmichael, Managing Director, Health Innovation & Venture Services, MaRS Discovery District

The Redefining Early Stage Investments (RESI) Conference is going abroad for the first time. RESI on MaRS will take place on June 23rd in Toronto, the heart of Canada's financial and health industries, where early stage investment in life sciences and digital health is on the cusp of a major breakthrough.

Take the launch of Johnson & Johnson's JLABS @ Toronto in May - also a first outside the United States, and in the very same building RESI will take place, the 1.5-million-square-foot building that is MaRS Discovery District. Or the recently announced centre for advanced therapeutic cell technologies, the first of its kind in the world, which is also moving into MaRS thanks to a $40-million collaboration between the government of Canada, GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM)...

By Dennis Ford, Founder & CEO, LSN

LSN is laser focused on the early stage investment dynamic; the ever changing relationship between buyer and seller, between investor and fundraising CEO/scientist-entrepreneur. LSN staff program the content to be specifically about investors detailing their investment processes to the entrepreneur audience - RESI's panels and workshops are selected for relevance to early stage investment.

After the investor landscape morphed, LSN created RESI to be a venue to feature all the players in the early stage investment arena. LSN tries hard to present current state-of-the-state content relevant to the investor marketplace. It's not just about venture capital firms; there are nine other categories of investor that LSN invites to RESI, including Angels, Corporate VCs, Family Offices, Large Pharma/Med Device corporations, and Foundations...

By Nono Hu, Director of Marketing, LSN

This week at RESI@TMCx, thirty companies from the biotech, medical device, diagnostic and healthcare IT sectors competed in the RESI Innovation Challenge. From among the applications we received, these companies were selected by LSN's scientific review board to present their technologies in an exhibition-style format while RESI attendees cast their votes on the best innovations on display. Here are the top 3 winners!

First Prize Winner: GeneSegues Therapeutics
Laura Brod, CEO, GeneSegues

Second Prize Winner: GreenLight Medical
Austin Dirks, CEO, CO-Founder, GreenLight Medical

Third Prize Winner: Adhesys Medical
Alexander Schuller, President, Laurence Zhu, Analyst from Adhesys with Emmanuelle Schuler Head of JLABS@TMC


Life Science Nation | 9B Hamilton Place | Boston | MA | 02108